Phathom Pharmaceuticals News and Activities

Phathom Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Phathom Pharmaceuticals is a company listed under the stock ticker PHAT (US).

View the org chart displaying its 28 main executives

Most searched biographies at Phathom Pharmaceuticals

• Steven Basta, President and Chief Executive Officer and Director
• Asit Parikh, Director
• Frank Karbe, Director

Popular executive movements at Phathom Pharmaceuticals

• Sanjeev Narula has joined the company as Chief Financial and Business Officer  (posted on October 6 2025).

Create your alert
to follow the executive moves at Phathom Pharmaceuticals.

Phathom Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Phathom Pharmaceuticals

• Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022 | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital | Phathom Pharmaceuticals, Inc.
• Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults | Phathom Pharmaceuticals, Inc.
• View more press releases Close

Social media about Phathom Pharmaceuticals

• Phathom Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Phathom Pharmaceuticals on LinkedIn, X (Twitter) & YouTube